Analysis of gene expression changes in relation to toxicity and tumorigenesis in the livers of Big Blue transgenic rats fed comfrey (Symphytum officinale)

BMC Bioinformatics

Volumn 7, Issue SUPPL.2, 2006, Pages

  Mei, Nan ^a   Guo, Lei ^a   Zhang, Lu ^b,c   Shi, Leming ^a   Sun, Yongming Andrew ^b   Fung, Chris ^b   Moland, Carrie L ^a   Dial, Stacey L ^a   Fuscoe, James C ^a   Chen, Tao ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b APPLIED BIOSYSTEMS   (United States)

^c Solexa Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIFFERENTIALLY EXPRESSED GENE; EXPERIMENTAL ANIMALS; GENE EXPRESSION PROFILES; GENE EXPRESSION STUDIES; MECHANISTIC SCHEME; MUTATION INDUCTION; PATHOLOGICAL CHANGES; PYRROLIZIDINE ALKALOID;

AGRICULTURE; ANIMALS; BIOASSAY; ENDOTHELIAL CELLS; NUTRITION; PLANTS (BOTANY); RATS; TOXICITY; TUMORS;

GENE EXPRESSION;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL DAMAGE; COMFREY; CONTROLLED STUDY; DIET; ENDOTHELIUM CELL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; LIVER CARCINOGENESIS; LIVER FIBROSIS; LIVER INJURY; LIVER TOXICITY; MALE; METABOLISM; MICROARRAY ANALYSIS; MUTATION RATE; NONHUMAN; PLANT ROOT; RAT; STATISTICAL SIGNIFICANCE; TRANSGENIC RAT; TREATMENT DURATION; ANIMAL; ANIMAL FOOD; CELL TRANSFORMATION; CHEMICALLY INDUCED DISORDER; CHEMISTRY; FISCHER 344 RAT; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; MUTATION; PATHOLOGY;

ANIMALIA; RATTUS; SYMPHYTUM; SYMPHYTUM OFFICINALE;

ANIMAL FEED; ANIMALS; BODY WEIGHT; CELL TRANSFORMATION, NEOPLASTIC; COMFREY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; LIVER NEOPLASMS; MALE; MUTATION; RATS; RATS, INBRED F344; RATS, TRANSGENIC;

EID: 33947331672     PISSN: None     EISSN: 14712105     Source Type: Journal    
DOI: 10.1186/1471-2105-7-S2-S16     Document Type: Article

References (58)

1. Winship KA: Toxicity of comfrey. Adverse Drug React Toxicol Rev 1991, 10(1):47-59.
2. Rode D: Comfrey toxicity revisited. Trends Pharmacol Sci 2002, 23(11):497-499.
3. Fu PP, Xia Q, Lin G, Chou MW: Pyrrolizidinealkaloids - genotoxicity, metabolism enzymes, metabolic activation, and mechanisms. Drug Metab Rev 2004, 36(1):1-55.
4. Prakash AS, Pereira TN, Reilly PE, Seawright AA: Pyrrolizidine alkaloids in human diet. Mutat Res 1999, 443(1-2):53-67.
5. USFDA, Center for Food Safety and Applied Nutrition: FDA advises dietary supplement manufacturers to remove comfrey products from the market. FDA 2001 [http://vm.cfsan.fda.gov/~dms/dspltr06.html].
6. Weston CF, Cooper BT, Davies JD, Levine DF: Veno-occlusive disease of the liver secondary to ingestion of comfrey. Br Med J (Clin Res Ed) 1987, 295(6591):183.
7. Ridker PM, Ohkuma S, McDermott WV, Trey C, Huxtable RJ: Hepatic venocclusive disease associated with the consumption of pyrrolizidine-containing dietary supplements. Gastroenterology 1985, 88(4):1050-1054.
8. DeLeve LD, Shulman HM, McDonald GB: Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002, 22(1):27-42.
9. Hirono I, Mori H, Haga M: Carcinogenic activity of Symphytum officinale. J Natl Cancer Inst 1978, 61(3):865-869.
10. Mei N, Guo L, Fu PP, Heflich RH, Chen T: Mutagenicity of comfrey (Symphytum Officinale) in rat liver. Br J Cancer 2005, 92(5):873-875.
11. DeLeve LD, Wang X, Kanel GC, Ito Y, Bethea NW, McCuskey MK, Tokes ZA, Tsai J, McCuskey RS: Decreased hepatic nitric oxide production contributes to the development of rat sinusoidal obstruction syndrome. Hepatology 2003, 38(4):900-908.
12. Paradis V, Bieche I, Dargere D, Cazals-Hatem D, Laurendeau I, Saada V, Belghiti J, Bezeaud A, Vidaud M, Bedossa P, et al.: Quantitative gene expression in Budd-Chiari syndrome: A molecular approach to the pathogenesis of the disease. Gut 2005, 54(12):1776-1781.
13. Kim NC, Oberlies NH, Brine DR, Handy RW, Wani MC, Wall ME: Isolation of symlandine from the roots of common comfrey (Symphytum officinale) using countercurrent chromatography. J Nat Prod 2001, 64(2):251-253.
14. Schaneberg BT, Molyneux RJ, Khan IA: Evaporative light scattering detection of pyrrolizidine alkaloids. Phytochem Anal 2004, 15(1):36-39.
15. Stickel F, Seitz HK: The efficacy and safety of comfrey. Public Health Nutr 2000, 3(4A):501-508.
16. Couet CE, Crews C, Hanley AB: Analysis, separation, and bioassay of pyrrolizidine alkaloids from comfrey (Symphytum officinale). Nat Toxins 1996, 4(4):163-167.
17. Huxtable RJ, Luthy J, Zweifel U: Toxicity of comfrey-pepsin preparations. N Engl J Med 1986, 315(17):1095.
18. Bach N, Thung SN, Schaffner F: Comfrey herb tea-induced hepatic veno-occlusive disease. Am J Med 1989, 87(1):97-99.
19. Ridker PM, McDermott WV: Comfrey herb tea and hepatic veno-occlusive disease. Lancet 1989, 1(8639):657-658.
20. Yeong ML, Swinburn B, Kennedy M, Nicholson G: Hepatic venoocclusive disease associated with comfrey ingestion. J Gastroenterol Hepatol 1990, 5(2):211-214.
21. Yeong ML, Clark SP, Waring JM, Wilson RD, Wakefield SJ: The effects of comfrey derived pyrrolizidine alkaloids on rat liver. Pathology 1991, 23(1):35-38.
22. DeLeve LD, McCuskey RS, Wang X, Hu L, McCuskey MK, Epstein RB, Kanel GC: Characterization of a reproducible rat model of hepatic veno-occlusive disease. Hepatology 1999, 29(6):1779-1791.
23. Svoboda DJ, Reddy JK: Malignant tumors in rats given lasiocarpine. Cancer Res 1972, 32(5):908-913.
24. Hirono I, Haga M, Fujii M, Matsuura S, Matsubara N, Nakayama M, Furuya T, Hikichi M, Takanashi H, Uchida E, et al.: Induction of hepatic tumors in rats by senkirkine and symphytine. J Natl Cancer Inst 1979, 63(2):469-472.
25. Zhou S, Koh HL, Tao Y, Gong ZY, Lee EJ: Herbal bioactivation: the good, the bad and the ugly. Life Sci 2004, 74(8):935-968.
26. Salat C, Holler E, Kolb HJ, Reinhardt B, Pihusch R, Wilmanns W, Hiller E: Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. Blood 1997, 89(6):2184-2188.
27. Kumar S, DeLeve LD, Kamath PS, Tefferi A: Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. Mayo Clin Proc 2003, 78(5):589-598.
28. Bauer M, BauRr I: Heme oxygenase-1: redox regulation and role in the hepatic response to oxidative stress. Antioxid Redox Signal 2002, 4(5):749-758.
29. Oe H, Kaido T, Mori A, Onodera H, Imamura M: Hepatocyte growth factor as well as vascular endothelial growth factor gene induction effectively promotes liver regeneration after hepatectomy in Solt-Farber rats. Hepatogastroenterology 2005, 52(65):1393-1397.
30. Gold EJ, Francis RJ, Zimmermann A, Mellor SL, Cranfield M, Risbridger GP, Groome NP, Wheatley AM, Fleming JS: Changes in activin and activin receptor subunit expression in rat liver during the development of CCl4-induced cirrhosis. Mol Cell Endocrinol 2003, 201(1-2):143-153.
31. Yeong ML, Wakefield SJ, Ford HC: Hepatocyte membrane injury and bleb formation following low dose comfrey toxicity in rats. Int J Exp Pathol 1993, 74(2):211-217.
32. Bataller R, Brenner DA: Liver fibrosis. J Clin Invest 2005, 115(2):209-218.
33. Sanz S, Pucilowska JB, Liu S, Rodriguez-Ortigosa CM, Lund PK, Brenner DA, Fuller CR, Simmons JG, Pardo A, Martinez-Chantar ML, et al.: Expression of insulin-like growth factor I by activated hepatic stellate cells reduces fibrogenesis and enhances regeneration after liver injury. Gut 2005, 54(1):134-141.
34. Marra F: Chemokines in liver inflammation and fibrosis. Front Biosci 2002, 7:d1899-1914.
35. Mei N, Chou MW, Fu PP, Heflich RH, Chen T: Differential mutagenicity of riddelliine in liver endothelial and parenchymal cells of transgenic big blue rats. Cancer Lett 2004, 215(2):151-158.
36. Mei N, Heflich RH, Chou MW, Chen T: Mutations induced by the carcinogenic pyrrolizidine alkaloid riddelliine in the liver cII gene of transgenic big blue rats. Chem Res Toxicol 2004, 17(6):814-818.
37. Hong HL, Ton TV, Devereux TR, Moomaw C, Clayton N, Chan P, Dunnick JK, Sills RC: Chemical-specific alterations in ras, p53, and beta-catenin genes in hemangiosarcomas from B6C3F1 mice exposed to o-nitrotoluene or riddelliine for 2 years. Toxicol Appl Pharmacol 2003, 191(3):227-234.
38. Nyska A, Moomaw CR, Foley JF, Maronpot RR, Malarkey DE, Cummings CA, Peddada S, Moyer CF, Allen DG, Travlos G, et al.: The hepatic endothelial carcinogen riddelliine induces endothelial apoptosis, mitosis, S phase, and p53 and hepatocytic vascular endothelial growth factor expression after short-term exposure. Toxicol Appl Pharmacol 2002, 184(3):153-164.
39. Hennings H, Glick AB, Greenhalgh DA, Morgan DL, Strickland JE, Tennenbaum T, Yuspa SH: Critical aspects of initiation, promotion, and progression in multistage epidermal carcinogenesis. Proc Soc Exp Biol Med 1993, 202(1):1-8.
40. Loeb LA: A mutator phenotype in cancer. Cancer Res 2001, 61(8):3230-3239.
41. Friedberg EC: How nucleotide excision repair protects against cancer. Nat Rev Cancer 2001, 1(1):22-33.
42. Cheo DL, Burns DK, Meira LB, Houle JF, Friedberg EC: Mutational inactivation of the xeroderma pigmentosum group C gene confers predisposition to 2-acetylaminofluorene-induced liver and lung cancer and to spontaneous testicular cancer in Trp53-/-mice. Cancer Res 1999, 59(4):771-775.
43. Nakashima Y, Ono T, Yamanoi A, El-Assal ON, Kohno H, Nagasue N: Expression of gap junction protein connexin32 in chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. J Gastroenterol 2004, 39(8):763-768.
44. Sheen IS, Jeng KS, Wang PC, Shih SC, Chang WH, Wang HY, Chen CC, Shyung LR: Are gap junction gene connexins 26, 32 and 43 of prognostic values in hepatocellular carcinoma? A prospective study. World J Gastroenterol 2004, 10(19):2785-2790.
45. Frommel TO, Yong S, Zarling EJ: Immunohistochemical evaluation of Bcl-2 gene family expression in liver of hepatitis C and cirrhotic patients: A novel mechanism to explain the high incidence of hepatocarcinoma in cirrhotics. Am J Gastroenterol 1999, 94(1):178-182.
46. Duan XX, Ou JS, Li Y, Su JJ, Ou C, Yang C, Yue HF, Ban KC: Dynamic expression of apoptosis-related genes during development of laboratory hepatocellular carcinoma and its relation to apoptosis. World J Gastroenterol 2005, 11(30):4740-4744.
47. Kaido T, Imamura M: Cepatocyte growth factor: clinical implications in hepatobiliary pancreatic surgery. J Hepatobiliary Pancreat Surg 2001, 8(1):65-75.
48. Drucker C, Parzefall W, Teufelhofer O, Grusch M, Ellinger A, Schulte-Hermann R, Grasl-Kraupp B: Non-parenchymal liver cells support the growth advantage in the first stages of hepatocarcinogenesis. Carcinogenesis 2006, 27(1):152-161.
49. Cangul H: Hypoxia upregulates the expression of the NDRG1 gene leading to its overexpression in various human cancers. BMC Genet 2004, 5:27.
50. He J, Zhou R: [Correlation of NDRG1 gene with liver tissue differentiation and hepatocarcinogenesis]. Beijing Da Xue Xue Bao 2003, 35(5):471-475.
51. Yasui K, Arii S, Zhao C, Imoto I, Ueda M, Nagai H, Emi M, Inazawa J: TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas. Hepatology 2002, 35(6):1476-1484.
52. Spruck CH, Won KA, Reed SI: Deregulated cyclin E induces chromosome instability. Nature 1999, 401(6750):297-300.
53. Hollander MC, Sheikh MS, Bulavin DV, Lundgren K, Augeri-Henmueller L, Shehee R, Molinaro TA, Kim KE, Tolosa E, Ashwell JD, et al.: Genomic instability in Gadd45a-deficient mice. Nat Genet 1999, 23(2):176-184.
54. Gramantieri L, Chieco P, Giovannini C, Lacchini M, Trere D, Grazi GL, Venturi A, Bolondi L: GADD45-alpha expression in cirrhosis and hepatocellular carcinoma: Relationship with DNA repair and proliferation. Hum Pathol 2005, 36(11):1154-1162.
55. Asselah T, Bieche I, Laurendeau I, Paradis V, Vidaud D, Degott C, Martinot M, Bedossa P, Valla D, Vidaud M, et al.: Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology 2005, 129(6):2064-2075.
56. Cariello NF: Software for the analysis of mutations at the human hprt gene. Mutat Res 1994, 312(2):173-185.
57. Adams WT, Skopek TR: Statistical test for the comparison of samples from mutational spectra. J Mol Biol 1987, 194(3):391-396.
58. Fang H, Tong W, Perkins R, Shi L, Hong H, Cao X, Xie Q, Yim SH, Ward JM, Pitot HC, et al.: Bioinformatics approaches for crossspecies liver cancer analysis based on microarray gene expression profiling. BMC Bioinformatics 2005, 6(Suppl 2S6 [http://].